“We’re working on a clinical trial and epidemiological studies to uncover ways to prevent diabetes and the consequences of diabetes and dysglycemia,” says Dr. Gerstein, professor in the departments of medicine and clinical epidemiology and biostatistics, and is director of McMaster’s division of endocrinology and metabolism. He is also director of the Diabetes Care and Research Program and endocrinology service at Hamilton Health Sciences Corporation.

“The clinical trial and epidemiological studies we’re doing are directly applicable to people with diabetes and people at risk of diabetes. We’re identifying therapies and approaches that can be implemented immediately.”

Dr. Gerstein is leader of the DREAM study (Diabetes Reduction Approaches with ramipril and rosiglitazone Medications), an international clinical trial testing ways to prevent type 2 diabetes. He was also the key investigator of a study on use of a drug in preventing both kidney and cardiovascular disease in high-risk people with diabetes.

In 1999 he won the Canadian Diabetes Association Young Scientist Award and the Frederick G. Banting Award.

< BACK TO FACES OF INNOVATION